A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
NCT ID: NCT01031225
Last Updated: 2014-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
113 participants
INTERVENTIONAL
2009-11-30
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
NCT01173523
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
NCT01348126
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
NCT01579994
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT01562015
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
NCT01798485
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
STA 9090
STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
STA 9090
STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Availability of tissue for analysis
* ECOG Performance Status 0 or 1
* Adequate organ function as defined in the protocol.
* Must be at least 18 years old and able and willing to sign a written informed consent document
Exclusion Criteria
* Women who are pregnant or lactating
* Ventricular ejection fraction \< or = to 55% at baseline
* Any uncontrolled intercurrent illness
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Synta Pharmaceuticals Corp.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Cancer Center; University of Arizona
Tucson, Arizona, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
City of Hope Medical Center
Duarte, California, United States
UCLA Health System
Santa Monica, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Emory University- Winship Cancer Institute
Atlanta, Georgia, United States
Rush University Medical Center
Chicago, Illinois, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Nevada Cancer Institute
Las Vegas, Nevada, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
University of North Carolina, Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Piedmont Hematology Oncology Associates
Winston-Salem, North Carolina, United States
Oregon Health and Science University
Portland, Oregon, United States
Penn State Hershey Cancer Institute
Hershey, Pennsylvania, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Swedish Medical Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9090-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.